Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA platform to treat or prevent diseases such as cancer. They did not include ...
He also worked on The Journal’s publishing desk; as a writer and editor covering stocks at Barron’s; as an editor of features at MarketWatch; and on product development efforts at The Journal.  ...
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
A newly discovered bat coronavirus uses the same cell-surface protein to gain entry into human cells as the Sars-CoV-2 virus ...
Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...
Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...
An epidemiologist said the Franklin County resolution was "based on conspiracy and misinformation against the COVID-19 ...
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic began—proof that health authorities had planned the pandemic in advance.
Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...